Cyberonics Depression Approval Contingent On Dosing Trial, Registry
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics will start a 450-patient, three-year dosing trial in order to gain PMA approval for its VNS Therapy neuromodulation device for use in treatment-resistant depression patients